Talnetant (SB-223,412) is a neurokinin 3 receptor antagonist developed by GlaxoSmithKline, which is being researched for several functions (primarily treatment of irritable bowel syndrome, despite a 2007 study finding no statistically significant improvement in rectal hypersensitivity over placebo).

Its use as a potential antipsychotic drug for the treatment of schizophrenia has also been discontinued.

[1][2][3][4] This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.